N-Terminal Capping of the αO-Conotoxin Analogue GeX-2 Improves the Serum Stability and Selectivity toward the Human α9α10 Nicotinic Acetylcholine Receptor
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xiao Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266…. Hauptthemen laut MEDLINE: Receptors, Nicotinic, Conotoxins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Australian Research Council, Qingdao National Laboratory for Marine Science and Technology, National Natural Science Foundation of China.
Abstract (Originalsprache)
α9α10 nicotinic acetylcholine receptors (nAChRs) are a promising nonopioid analgesic target, with α9α10 nAChR antagonists showing efficacy against chemotherapy-induced hyperalgesia and allodynia. GeX-2, a potent analgesic conotoxin antagonist of α9α10 nAChRs, has limited serum stability. This study improved GeX-2 stability by capping its N-terminal with fatty acids or polyethylene glycol chains, which enhanced its serum stability but eliminated activity at G protein-coupled γ-aminobutyric acid type B (GABAB) receptor-coupled CaV2.2 channels while preserving activity at α9α10 nAChRs. In vivo, α9α10 nAChRs antagonism alone did not alleviate neuropathic pain, highlighting the importance of GABAB receptor-coupled CaV2.2 channels in GeX-2's antinociceptive effects in the chronic constriction injury rat model. The GeX-2 analogue, with an N-terminal methyl group, showed improved activity and selectivity for α9α10 nAChRs, increased serum half-life, and strong analgesic effects in oxaliplatin-induced cold allodynia models. AlphaFold3 and molecular dynamics simulations provided insights into the binding modes and the effects of N-terminal capping, which informed future peptide therapeutic developments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
- Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao 266237, China.
- Illawarra Health and Medical Research Institute (IHMRI), Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2522, Australia.
- Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao 266042, China.
- Shandong Academy of Pharmaceutical Sciences 989 Xinluo Street, Jinan 250101, China.
ORCID-Profile: Han-Shen Tae, Tao Jiang, David J Adams, Rilei Yu
Förderung
- Australian Research Council
- Qingdao National Laboratory for Marine Science and Technology
- National Natural Science Foundation of China
- Jinan Innovation Team Project
- Shandong Major Innovation Project
- Shandong Supporting Funds for Talents
Zitieren
APA
Li, X., Zhou, S., Tae, H. S., Wang, S., Li, T., Cai, W., Jiang, T., Adams, D. J., & Yu, R. (2024). N-Terminal Capping of the αO-Conotoxin Analogue GeX-2 Improves the Serum Stability and Selectivity toward the Human α9α10 Nicotinic Acetylcholine Receptor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01758
Vancouver
Li X, Zhou S, Tae HS, Wang S, Li T, Cai W, et al. N-Terminal Capping of the αO-Conotoxin Analogue GeX-2 Improves the Serum Stability and Selectivity toward the Human α9α10 Nicotinic Acetylcholine Receptor. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01758
BibTeX
@article{Li2024,
author = {Li, Xiao and Zhou, Shenglu and Tae, Han-Shen and Wang, Shoushi and Li, Tianmiao and Cai, Wenqing and Jiang, Tao and Adams, David J and Yu, Rilei},
title = {N-Terminal Capping of the αO-Conotoxin Analogue GeX-2 Improves the Serum Stability and Selectivity toward the Human α9α10 Nicotinic Acetylcholine Receptor},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01758}
}
EUVIMED